by Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It is a leading cause of maternal and fetal morbidity and mortality worldwide. The current methods for preeclampsia diagnosis include blood pressure monitoring, urine analysis for protein, and blood tests to check liver and kidney function. However, there is a need for better diagnostic methods with high sensitivity and specificity for early detection. This has prompted increased investments by pharmaceutical and diagnostics companies in developing novel tests using biomarkers, imaging techniques, and other approaches.
The global Preeclampsia Diagnostics Market is estimated to be valued at Us$ 1,587.53 Mn in 2023 and is expected to exhibit a CAGR Of 5.6% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing R&D Investments into Novel Diagnostic Tests: As mentioned in the heading, growing investments by market players as well as research institutes in the development and validation of innovative preeclampsia diagnostic tests using novel biomarkers and imaging modalities is expected to drive market growth over the forecast period. Some key areas attracting R&D investments include placental biomarkers, angiogenic factors, and molecular imaging techniques.
Early and Timely Diagnosis Needs: Lack of early detection is a major challenge in preeclampsia management, resulting in high mortality and morbidity rates. The growth of the market can be attributed to growing need for reliable diagnostic tests that can detect preeclampsia at early stages to enable timely treatment interventions.
Segment Analysis
The preeclampsia diagnostics market is segmented into product, test type, end-user, and region. Based on product, the market is segmented into blood pressure monitors, uric acid tests, Doppler ultrasonography devices, and others. Among these, the blood pressure monitors segment holds the largest share as blood pressure monitoring is essential to diagnose and manage preeclampsia. Based on test type, the market is divided into urine analysis, blood tests, ultrasound. The blood tests segment dominates as it helps detect protein in the urine and other biomarkers to confirm a diagnosis of preeclampsia.
PEST Analysis
Political: Governments across countries are increasing healthcare expenditure to improve maternal care. Favorable regulations to expedite product approvals will support market growth.
Economic: Rising disposable incomes in developing nations are increasing access to advanced diagnostics. Growing patient awareness about condition management is propelling the demand.
Social: Prevalence of lifestyle diseases and growing risk of pregnancy complications are major concerns. Better access to insurance and treatment seeks to reduce maternal mortality.
Technological: Companies are launching novel biomarker-based tests with high accuracy and minimal invasiveness. Artificial intelligence and cloud connectivity enhance data management in remote care.
Key Takeaways
The Global Preeclampsia Diagnostics Market Demand is expected to witness high growth. The global preeclampsia diagnostics market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
The North American region dominates the market currently due to widespread healthcare infrastructure and high adoption of advanced technologies. Asia Pacific region is expected to witness fastest growth during the forecast period supported by growing geriatric population, increasing healthcare spending, and rising incidence of preeclampsia.
Key players operating in the preeclampsia diagnostics market are AstraZeneca, CorMedix, Inc., Citius Pharmaceuticals, Fresenius Medical Care, Glenmark Pharmaceuticals Ltd., Geistlich Pharma, Merck & Co., Inc., Pfizer, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd.
Key players related content comprises Key players operating in the preeclampsia diagnostics market are focusing on new product launches. For instance, in 2021, AstraZeneca launched a Phase III clinical trial to evaluate Anthropic’s experimental AI method for detecting preeclampsia in pregnant women using routine blood tests.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
